Physician profile
Daniel R Brown
NPI 1548374887
$135,744.70
in general payments reported to CMS, 2019-2025
25 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $894 · 2021: $2,074 · 2022: $230 · 2023: $823 · 2024: $59K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $131K · Travel and Lodging: $601 · Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $131,314.00 |
| Travel and Lodging | $600.56 |
| Food and Beverage | $463.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $131,996.00 | 2023-2025 | |
| Paragon 28, INC. | $1,127.72 | 2021 | |
| Treace Medical Concepts, INC. | $784.16 | 2021 | |
| Elite Orthopedics, LLC | $670.78 | 2020 | |
| Smith+Nephew, INC. | $261.38 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $199.00 | 2021-2025 | Nuzyra |
| Triad Life Sciences INC. | $168.71 | 2022 | |
| Kci USA, INC. | $87.67 | 2020-2023 | Kerramax Care, Activ.A.C., Promogran Prisma |
| Organogenesis INC. | $68.69 | 2019 | |
| Averitas Pharma INC. | $62.34 | 2023 | Qutenza |
| Amgen INC. | $42.59 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $41.41 | 2019-2023 | Krystexxa |
| Abbvie INC. | $40.21 | 2021-2022 | |
| Kerecis Limited | $23.78 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Nevro Corp. | $23.26 | 2023 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.38 | 2022 | |
| Integra Lifesciences Corporation | $17.29 | 2020 | |
| Bioventus LLC | $17.01 | 2019 | |
| Zimvie INC. | $15.51 | 2022 | |
| Sandoz INC. | $15.23 | 2019 | |
| Heron Therapeutics, INC. | $14.16 | 2025 | Zynrelef |
| Merck Sharp & Dohme LLC | $13.74 | 2019 | |
| Lifenet Health | $13.09 | 2024 | Theragenesis Wound Matrix |
| Stryker Corporation | $12.35 | 2021 | |
| Zimmer Biomet Holdings, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.